In the previous trading session, Indian benchmark indices witnessed cautious movements as investors tracked global market developments along with domestic corporate announcements and sector-specific updates.
Market participants also continued to monitor company-level developments including regulatory approvals, mergers and acquisitions, order inflows and pricing decisions that could influence near-term stock movements.
Tata Motors announced a price increase of up to 1.5% across its commercial vehicle range, effective from April 1, 2026. The company stated that the revision is aimed at partially offsetting the impact of rising commodity prices and increasing input costs.
Promoter Sagar Cements plans to sell up to 66.76 lakh equity shares of Andhra Cements, representing around 7.24% of the company’s total paid-up equity. The offer for sale is scheduled for March 17–18 with a floor price of ₹52 per share.
Sun Pharma announced that the US Food and Drug Administration has accepted for review the supplemental Biologics License Application for ILUMYA for the treatment of adults suffering from active psoriatic arthritis. The regulatory decision is expected by October 29, 2026.
GMDC has signed a Memorandum of Understanding with the National Mineral Development Corporation to explore collaboration opportunities in the rare earth elements sector. The partnership aims to evaluate the development of an integrated rare earth value chain in Gujarat.
The board of Axiscades Technologies has approved the acquisition of the remaining 24% stake in Cades Studec Technologies India from STUDEC SAS, France. Following the transaction, Cades Studec Technologies India will become a wholly owned subsidiary of the company.
Power Mech Projects secured an order worth ₹709.56 crore from Adani Infrastructure Management Services. The contract covers operations and maintenance services, including overhauling activities at the 5x660 MW thermal power plant located in Tiroda, Maharashtra.
Zydus Lifesciences’s subsidiary, Sentynl Therapeutics Inc. in the United States, is entering into a licensing agreement with Korean firm PRG S&T for its investigational molecule Progerinin (SLC-D011). The drug is being developed for the treatment of Hutchinson-Gilford Progeria Syndrome, a rare genetic disorder.
Bajaj Electricals announced that it has signed a definitive agreement to acquire the intellectual property and brand rights of Morphy Richards in India and select South Asian markets for ₹141.4 crore. The acquisition is expected to strengthen the company’s position in the small domestic appliances segment.
Read More: Ipca Laboratories, Aurobindo Pharma, Glenmark Share Price Rally As Nifty Pharma Hits 52-Week High!
Corporate developments including stake sales, regulatory reviews, acquisitions and fresh project orders are expected to drive stock-specific activity during today’s trading session.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks. Read all related documents carefully before investing.
Published on: Mar 17, 2026, 8:08 AM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
EN